Tonix Pharmaceuticals Holding (TNXP) - מקדם חוב לטווח ארוך להון

The visual representation of Tonix Pharmaceuticals (TNXP) quotes on the GURU.Markets platform allows for an assessment of the debt load of the company, whose future revenues rely on the commercialization of Tonmya for the therapy of PTSD and fibromyalgia. This indicator stands at 0.00. Business value growth depends on the outcomes of final drug tests and cost reductions. Meanwhile, the firm's environmental footprint is minimal due to the absence of its own production facilities.

Amid restructuring and the concentration of resources by Tonix Pharmaceuticals (TNXP) on the final stages of clinical trials, managing the debt load becomes a critical survival factor for the biotech firm. This indicator correlates liabilities with maturities exceeding one year with net equity, allowing for an assessment of financial stability via the ratio of long-term borrowed capital to equity and identifying undercapitalization risks during price volatility.